Cat. No. | Product name | CAS No. |
DC11929 |
ME-344
A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM. |
1374524-68-1 |
DC11866 |
AZD 3147
Featured
A potent, selective dual mTORC1 and mTORC2 inhibitor with enzyme IC50 of 1.5 nM. |
1101810-02-9 |
DC1001 |
FK-506 (Tacrolimus)
Featured
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties. |
104987-11-3 |
DC5084 |
AZD-8055
Featured
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. |
1009298-09-2 |
DC8377 |
CC-115
Featured
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity. |
1228013-15-7 |
DC8497 |
CC-223
Featured
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM). |
1228013-30-6 |
DC10125 |
CZ415
Featured
CZ415 is a potent and highly selective mTOR inhibitor. |
1429639-50-8 |
DC1501 |
Everolimus
Featured
Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM. |
159351-69-6 |
DC7014 |
GPI-1046
For the detailed information of GPI-1046, the solubility of GPI-1046 in water, the solubility of GPI-1046 in DMSO, the solubility of GPI-1046 in PBS buffer, the animal experiment (test) of GPI-1046, the cell expriment (test) of GPI-1046, the in vivo, in vitro and clinical trial test of GPI-1046, the EC50, IC50,and Affinity of GPI-1046, Please contact DC Chemicals.. |
186452-09-5 |
DC11151 |
ICSN3250 hydrochloride
ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors. |
1561902-79-1 |
DC11150 |
ICSN3250
ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors. |
1561902-73-5 |
DC7171 |
INK-128(Sapanisertib)
Featured
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
1224844-38-5 |
DC3101 |
Ku-0063794
KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2 with IC50 ~10 nM. |
938440-64-3 |
DC7210 |
LY-303511(Nv-128)
Featured
LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K. |
154447-38-8 |
DC1006 |
OSI-027
Featured
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
936890-98-1 |
DC7482 |
Torkinib (PP242)
Featured
PP242 is a selective mTOR inhibitor with IC50 of 8 nM; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively; also showed slightly weaker activity against BRD4 (Kd= 1.7 uM). |
1092351-67-1 |
DC11816 |
RapaLink-1
Featured
RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin. |
1887095-82-0 |
DC1048 |
Rapamycin (Sirolimus)
Featured
Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor with IC50 of ~0.1 nM. - |
53123-88-9 |
DC11306 |
Secorapamycin A(Seco Rapamycin)
Featured
Seco-rapamycin(Secorapamycin A) is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.. |
147438-27-5 |
DCAPI1488 |
Temsirolimus
Featured
Temsirolimus is an inhibitor of ribosomal protein S6 phosphorylation and inhibits cell growth and clonogenic survival of cells in a concentration-dependent manner. |
162635-04-3 |
DC3117 |
Torin2
Featured
Torin 2 is a highly potent and selective mTOR inhibitor with IC50 of 0.25 nM, and also exhibits potent cellular activity against ATM/ATR/DNA-PK with EC50 of 28 nM, 35 nM and 118 nM, respectively. |
1223001-51-1 |
DC3118 |
Torin1
Featured
Torin1 is a potent inhibitor of mTOR with IC50 of 2-10 nM. |
1222998-36-8 |
DC5088 |
WYE125132
WYE125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor |
1144068-46-1 |
DC9514 |
Deforolimus
Featured
Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. IC50 value: 0.2 nM [1] Target: mTOR in vitro: Treatment of HT |
572924-54-0 |
DC41010 |
PQR626
Featured
PQR626 is an orally available, and brain-penetrant mTOR inhibitor extracted from patent WO2017198346A1, compound example 44, has an IC50 of 5 nM for mTOR. PQR626 can be used for the research of neurological disorder. |
1927857-98-4 |
DC44210 |
mTOR inhibitor-8
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells. |
2489196-70-3 |
DC44967 |
RMC-5552
Featured
RMC-5552 is a potent and selective inhibitor of mTORC1. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity. |
2382768-62-7 |
DC47252 |
RMC-6272
RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors. |
2382769-46-0 |
DC47559 |
Dihydroevocarpine
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity. |
15266-35-0 |
DC47560 |
(32-Carbonyl)-RMC-5552
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2). |
2382768-55-8 |
DC47561 |
MHY-1685
Featured
MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration. |
27406-31-1 |
DC47913 |
RMC-4529
RMC-4529 has an IC50 value of 1.0 nM against p-4E-BP1-(T37/46) in mTOR kinase cellular assay. |
2250059-27-7 |
DC48473 |
L-Leucine-13C6,15N
L-Leucine-13C6,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. |
202406-52-8 |
DC49290 |
L-Leucine-2-13C,15N
L-Leucine-2-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. |
285977-88-0 |
DC49291 |
L-Leucine-1-13C,15N
L-Leucine-1-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. |
80134-83-4 |
DC49293 |
L-Leucine-2-13C
L-Leucine-2-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. |
201612-66-0 |
DC49334 |
L-Leucine-18O2
L-Leucine-18O2 is the 18O-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway. |
73579-45-0 |
DC49377 |
RMC-4627
RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth. |
2250059-52-8 |
DC71016 |
CC214-2
CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB. |
1228012-18-7 |
DC71229 |
PP30
PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of mTOR with an IC50 of 80 nM. |
1092788-09-4 |
DC72910 |
CC214-1
CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC50 is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study. |
1021920-32-0 |
DC74258 |
NV-5297
NV-5297 (NV5297) is a novel small molecule mTORC1 pathway activator, modulates the Sestrin2-Gator2 interaction and activates the mTORC1 pathway in vitro and in vivo. |
2095886-40-9 |